title: Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains.
abstract: The difference between the binding of [3H]nemonapride and [3H]raclopride has been used to quantify dopamine D4 receptors in postmortem schizophrenic brain studies. Recent work, however, has suggested that at least part of the differential between [3H]nemonapride and [3H]raclopride binding may represent sigma rather than D4 receptor sites. We applied the nemonapride-raclopride subtraction method to postmortem, non-schizophrenic human striatum to examine the variation in dopaminergic receptor binding labeled by these ligands. Variation in sigma receptor binding labeled by [3H]nemonapride was studied in frontal cortex, striatum and cerebellum. Specific binding was defined by sulpiride (dopamine receptor ligand), PPAP (sigma receptor ligand) and haloperidol (mixed dopaminergic/sigma agent), respectively. Haloperidol defined a combination of sites, which were approximately the sum of the dopaminergic and sigma components defined by sulpiride and PPAP, respectively. Significant inter-individual variation in the amount of specific binding for dopaminergic and sigma receptor sites was observed. However, no significant nor consistent observation of striatal dopamine D4 receptors or D4-like binding sites was observed in the striatum even though two independent sets of tissues, with different dissections were used. The inconsistencies in some previous postmortem studies appear to be at least partially explained by the inclusion of both sigma and dopaminergic components in [3H]nemonapride binding and the inherent high inter-individual variability of the different components.
authors.affiliation: Department of Psychiatry and Human Behavior, University of California, Irvine, North Campus, 92697, USA.
authors.forename: S W
authors.initials: SW
authors.lastname: Tang
authors.forename: D M
authors.initials: DM
authors.lastname: Helmeste
authors.forename: H
authors.initials: H
authors.lastname: Fang
authors.forename: M
authors.initials: M
authors.lastname: Li
authors.forename: R
authors.initials: R
authors.lastname: Vu
authors.forename: W
authors.initials: W
authors.lastname: Bunney
authors.forename: S
authors.initials: S
authors.lastname: Potkin
authors.forename: E G
authors.initials: EG
authors.lastname: Jones
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides / Q000494:pharmacology*; D001923:Brain Chemistry / Q000187:drug effects*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D020891:Raclopride; D011954:Receptors, Dopamine / Q000187:drug effects*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism; D050638:Receptors, Dopamine D4; D017480:Receptors, sigma / Q000187:drug effects*; D012457:Salicylamides / Q000494:pharmacology*; D012559:Schizophrenia / Q000378:metabolism*
chemical_list: D001549:Benzamides; C493599:DRD4 protein, human; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D017480:Receptors, sigma; D012457:Salicylamides; D050638:Receptors, Dopamine D4; D020891:Raclopride; C030265:nemonapride